Pandemic-resilient Chinese healthcare companies in Investcorp’s sights with launch of new platform


Alternative investment major Investcorp has launched a new platform dedicated to backing Chinese healthcare companies.

The firm said it had bought minority equity stakes in Lu Daopei Medical Group and WeDoctor as part of the initiative.

Investcorp said the platform aims to create a portfolio of primary and secondary stakes in sector-leading Chinese healthcare companies that have remained resilient through the coronavirus pandemic, and are expected to experience accelerated growth in the post-Covid world.

Mohammed Alardhi, executive chairman of Investcorp, said, “Investcorp has been actively growing its presence in Asia as part of our strategy to provide our global clients with exposure to the strongest sectors and geographies around the world.

“The progress we have delivered on our expansion in Asia over the last two years, including establishing a world-class team and building our local expertise, has enabled us to take this significant next step in launching our first stand-alone investment platform in China.

“We believe that there are many attractive opportunities in the Chinese healthcare sector as this is a pivotal time to meet increasing demand for quality medical services and treatments.”

Lu Daopei Medical Group specialises in the field of hematology in China and is a pioneer of bone marrow transplantation, while WeDoctor is an online healthcare services company founded in 2010 by artificial intelligence expert Jerry Liao.

Last week Investcorp backed Chinese AI-controlled city and smart services developer Terminus Technologies.

Terminus, which was founded five years ago, is currently promoting the construction of a global network of the AI cities worldwide, in which many global cities have agreed to participate in, including Dubai and Shenyang.

Copyright © 2020 AltAssets

Get the latest PE News & Research delivered to your inbox every morning